In line with this, in models of lung and renal cell carcinoma, entinostat, a class I histone deacetylase inhibitor, improved the anti-tumor effect of anti-PD-1 antibodies by reducing the expression of Arg1, iNOS, and COX2 in MDSCs (60). Here, ARG1 is linked to neoplasm.